Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAS: Intensified consolidation strategies for very-high risk metastatic neuroblastoma with poor induction response
2015-003130-27Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Jun 2017
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised trial of Iobenguane I-131, topotecan and thiotepa in neuroblastoma (2 arms), sponsored by Gustave Roussy. Primary endpoint: Event-free survival. Started Jun 2017; status: terminated.
02
Drugs
Iobenguane I-131topotecanthiotepa
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2015-003130-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003130-27.